Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-ZG122 in moderate-to-severe asthma
NCT07054034Phase 2Active, not recruiting
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of MG-ZG122 in asthma, sponsored by Hunan Mabgeek Biotechnology. Started May 2025; status: active, not recruiting.
02
Drugs
MG-ZG122
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07054034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054034.